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Abstract
Background: Resistance to anoikis, which is defined as apoptosis induced by loss of integrin-mediated cell attachment to
the extracellular matrix, is a determinant of tumor progression and metastasis. We have previously identified the
mitochondrial Bit1 (Bcl-2 inhibitor of transcription) protein as a novel anoikis effector whose apoptotic function is
independent from caspases and is uniquely controlled by integrins. In this report, we examined the possibility that Bit1 is
suppressed during tumor progression and that Bit1 downregulation may play a role in tumor metastasis.
Methodology/Principal Findings: Using a human breast tumor tissue array, we found that Bit1 expression is suppressed in
a significant fraction of advanced stages of breast cancer. Targeted disruption of Bit1 via shRNA technology in lowly
aggressive MCF7 cells conferred enhanced anoikis resistance, adhesive and migratory potential, which correlated with an
increase in active Extracellular kinase regulated (Erk) levels and a decrease in Erk-directed phosphatase activity. These pro-
metastasis phenotypes were also observed following downregulation of endogenous Bit1 in Hela and B16F1 cancer cell
lines. The enhanced migratory and adhesive potential of Bit1 knockdown cells is in part dependent on their high level of Erk
activation since down-regulating Erk in these cells attenuated their enhanced motility and adhesive properties. The Bit1
knockdown pools also showed a statistically highly significant increase in experimental lung metastasis, with no differences
in tumor growth relative to control clones in vivo using a BALB/c nude mouse model system. Importantly, the pulmonary
metastases of Bit1 knockdown cells exhibited increased phospho-Erk staining.
Conclusions/Significance: These findings indicate that downregulation of Bit1 conferred cancer cells with enhanced anoikis
resistance, adhesive and migratory properties in vitro and specifically potentiated tumor metastasis in vivo. These results
underscore the therapeutic importance of restoring Bit1 expression in cancer cells to circumvent metastasis at least in part
through inhibition of the Erk pathway.
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Introduction
The loss of the anchorage dependence of normal epithelial cells
is one of the hallmarks of malignant cells [1,2] and is acquired
through resistance to detachment-induced apoptosis (anoikis) [3].
The ability of tumor cells to survive detachment and evade anoikis
may enable them to leave their original site, invade the
surrounding tissue and extracellular matrix, enter the blood or
lymphatic circulation, and eventually metastasize to secondary
sites. Since the acquisition of anoikis resistance is an important
determinant of transformation and metastatic potential [4],
suppression of the anoikis pathway may contribute to tumorigenic
and metastatic proficiency of malignant cells. This work analyzes
the potential role of the novel anoikis effector Bit1 in tumor
progression and metastasis.
Bit1 (Bcl2-inhibitor of transcription) is a mitochondrial protein
that is released to the cytosol following loss of cell attachment and
interacts with the Groucho/TLE family transcription factor AES
to induce caspase-independent apoptosis. Importantly, the Bit1
apoptotic activity can only be counteracted by intergrin-mediated
cell attachment and not by any anti-apoptotic factor such as bcl2,
bcl-xl and Akt [5]. Thus, Bit1 is sometimes regarded as a guardian
of anchorage-dependence. The anoikis function of Bit1 has been
demonstrated in several transformed and tumor cell lines. While
overexpression of mitochondrial Bit1 in cells enhances their
sensitivity to anoikis, downregulation of Bit1 expression renders
tumor cells as well as normal cells more resistant to anoikis [6].
Despite the well documented data on the potent pro-anoikis effect
of Bit1 on tumor cells, its role in tumor progression and metastasis
remains unknown.
There is evidence to suggest that the Bit1 anoikis pathway is
important in tumorigenesis. First, we have recently shown that
Bit1 negatively regulates the extracellular signal-regulated kinase
1/2 (Erk 1/2) survival signaling, a pathway which is activated in
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several malignacies [7,8,9]. Mouse embryonic fibroblasts (MEFs)
from Bit1 knockout mice and tumor cells in which Bit1 had been
downregulated by siRNA interference showed a marked increase
in Erk activation [10], and such elevated Erk activity in part
accounts for the enhanced anoikis resistance in Bit1 knockdown
cells. Considering the crucial role of the Erk signaling pathway in
tumorigenesis and metastasis [7,8,9], the Bit1-mediated Erk
regulation may influence tumorigenesis and/or the metastatic
process. Second, TLE1, a groucho transcriptional regulator that
counteracts Bit1/AES apoptosis, is an indicator of poor prognosis
in lymphoma patients [11] and a putative lung-specific oncogene
[12]. Recently, AES has been shown to be a suppressor of colon
cancer metastasis [13]. Taken together, these findings implicate
the Bit1/AES pathway in tumorigenesis and/or metastasis.
Considering the anoikis remains a critical barrier to transfor-
mation and metastasis, we examined the possibility that suppres-
sion or nonfunctionality of the Bit1 anoikis pathway may
contribute to tumor progression. In the present study, we found
that Bit1 expression is significantly downregulated in advanced
cases of breast cancer tissues as compared to the counterpart
normal breast tissue. Importantly, stable knockdown of Bit1
expression in lowly aggressive breast cancer MCF7 as well as in
B16F1 and Hela cells resulted in enhanced anoikis resistance,
adhesion, and migratory property. Consistent with these in vitro
data, the stable Bit1 knockdown cells also showed enhanced
metastasis in vivo. These findings implicate a role of Bit1 in
metastasis.
Results
Expression of Bit1 is reduced in invasive breast tumors
Since anoikis resistance is a determinant of tumor progression
and metastasis in tumor cells, we tested the possibility that the Bit1
anoikis pathway is suppressed in human mammary cancers. We
used immunohistochemistry to examine Bit1 expression in human
mammary tumor tissue array consisting of DCIS (Ductal
Carcinoma In situ lesions), invasive breast carcinomas, and
normal counterpart breast tissues using a rabbit affinity purified
anti-Bit1 antibody (Sigma). The specificity of this antibody has
been validated by the manufacturer and the Human Protein Atlas
Project. The normal mammary epithelium showed moderate to
strong cytoplasmic immunoreactivity for Bit1 (Figure 1A i-ii). The
majority of DCIS lesions (Figure 1A iii) retained similar Bit1
immunostaining as that of normal breast tissue. Interestingly, in
certain cases of DCIS lesions, epithelial cells that had filled the
breast duct had completely lost Bit1 expression while those
epithelial cells that remain in direct contact with the stroma
maintained Bit1 immunoreactivity (Figure 1A iv). In contrast to
Figure 1. Bit1 expression is downregulated in invasive breast tumors. A. Breast tumor tissue array slides were stained with affinity purified
anti-Bit1 (Sigma). Images are representative of each respective case type: normal breast 10X (i,ii), Ductal carcinoma in situ (DCIS) 10X (iii, iv), node
negative invasive breast carcinoma 10X (v, vi), and node positive invasive breast carcinoma 10x (vii, viii). B. The average staining intensity of each
subgroup was determined. While no significant difference was found between normal and DCIS subgroups, the normal/DCIS was statistically
significant (P,0.01) from the nodal negative- and nodal positive-invasive breast carcinomas using the ANOVA and subsequent Tukey post-hoc
analysis (see Materials and Methods). Further Tukey post-hoc analysis indicated a significant difference (*, P,0.05) between the invasive node
negative and invasive node positive breast carcinoma tissues. C. The distribution of staining intensity scores shows the change in staining pattern
between normal/DCIS and invasive case types. Scores were grouped as low (0–1), medium (2), and high (3). Data represent the ratio of the number of
samples in each group (low, medium, high) to the total number of samples.
doi:10.1371/journal.pone.0023840.g001
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normal and DCIS breast tissues, invasive breast carcinomas, both
nodal negative and nodal positive subgroups, showed reduced
cytoplasmic Bit1 immunoreactivity (Figure 1A v–viii). Quantifica-
tion of the average Bit1 staining (Figure 1B) confirmed the similar
Bit1 expression between the normal and DCIS subgroups and the
reduction of Bit1 immunoreactivity in invasive nodal negative and
positive breast carcinoma tissues as compared to normal/DCIS
subgroups. Importantly, we found that the higher grade invasive
breast tumor tissues (nodal metastasis positive subgroup) showed a
much lower average Bit1 staining (Figure 1B) as compared to
invasive node-negative subgroup. Consistent with these findings,
analysis of the distribution of staining intensity scores (Figure 1C)
showed that while the proportion of staining scores was similar
between normal and DCIS subgroups, Bit1 staining frequencies
varied dramatically between the normal/DCIS and the invasive
node-negative/node-positive subgroups with the node-positive
tumor tissues exhibiting the highest frequency of reduced Bit1
immunoreactivity. These findings indicate that Bit1 expression is
selectively lost in invasive breast carcinomas, suggesting that loss of
Bit1 may accompany the transition from DCIS to invasive
carcinoma during the progression of breast cancer.
Downregulating Bit1 in cultured cells results in enhanced
resistance to anoikis
To address the biological significance of Bit1 downregulation in
the aggressive phenotype of breast tumor cells, we suppressed Bit1
expression in the lowly aggressive mammary carcinoma MCF7
cell line which exhibits moderate levels of endogenous Bit1
(Figure 2A). Stable Bit1 knockdown and control clones were
generated via infection of MCF7 cells with lentiviral particles
containing Bit1 specific- or control- shRNAs. Several control and
Bit1 knockdown clones were pooled together to generate the
control shRNA and the Bit1 shRNA knockdown pools, respec-
tively. Immunoblotting analysis confirmed the downregulation of
endogenous Bit1 expression by 50–70% in the Bit1 knockdown
pool (Figure 2B). Since Bit1 is a novel anoikis regulator whose
apoptotic function is uniquely regulated by integrin-mediated cell
attachment [5], we then examined the impact of Bit1 downreg-
ulation on the anoikis sensitivity of MCF7 cells (Figure 2C and
2D). As compared to control pool, the Bit1 knockdown pool
exhibited significantly decreased level of apoptosis following
culture in suspension for 48 h as evidenced by decreased annexin
V staining (Figure 2C) and reduced level of DNA histone
Figure 2. Suppression of Bit1 expression enhances anoikis resistance. A. Total cell lysate derived from each respective breast cancer cell line
was subjected to SDS-PAGE and immunoblotting using a specific antibody to Bit1. The membrane was then reprobed with anti-b-actin antibody to
confirm equal loading of protein. B. Stable MCF7controlshRNA and Bit1shRNA knockdown pools were generated as described in Materials and
Methods, and the total cell lysates derived from controlshRNA and Bit1shRNA knockdown pools were subjected to immunobloting using a specific
antibody to Bit1. C and D. MCF7controlshRNA and Bit1shRNA knockdown pools were plated onto a polyhema coated or uncoated tissue culture
plates. Following 48 h in culture, cells were the stained with Annexin V, a marker of apoptosis, and the relative fluorescence intensities are shown (C).
In D, level of apoptosis was also quantified by measuring the amount of DNA histone fragments (Cell Death Elisa). E and F. The stable control shRNA
and Bit1shRNA knockdown pools were also generated from the B16F1 cell line. The resulting B16F1 controlshRNA and Bit1shRNA knockdown pools
were subjected to total cell lysate isolation, SDS-PAGE, and immunoblotting against a specific Bit1 antibody to confirm Bit1 downregulation (E). In F,
the B16F1 controlshRNA and Bit1shRNA knockdown pools were plated onto a polyhema coated or uncoated tissue culture plates for 48 h, and the
level of apoptosis was the quantified by measuring the amount of DNA histone fragments. In C, D, and F, three independent experiments were
performed in triplicates. *p,0.05 as compared with control cells (Student’s t test).
doi:10.1371/journal.pone.0023840.g002
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fragments (Figure 2D). In stark contrast, no significant differences
in the basal apoptosis were observed between the MCF7 Bit1
knockdown and control pools in attached conditions. The
observed enhanced anoikis resistance in MCF7-derived Bit1
knockdown pool of cells was also observed in the previously
generated stable HeLa cell Bit1 knockdown clones [10] and
following stable downregulation of Bit1 expression in the mouse
melanoma B16F1 cells (Figure 2E–F).
Suppressing Bit1 expression changes cell morphology
and enhances cell adhesion and migration
We observed that the stable Bit1 knockdown pool derived from
both the MCF7 and B16F1 cell lines showed a flatter and
stretched morphology relative to the corresponding the control
pool (Figure 3A and 3B). Targeted reduction of Bit1 in Hela cells
(Figure S1A) also exhibited a fibroblastoid and spindle shape-like
morphology. Consistent with their flatter and extended morphol-
ogy, the stable MCF7 Bit1 knockdown pool (Figure 3C) as well as
the B16F1 Bit1 knockdown pool (Figure 3D) adhered more
strongly to fibronectin and collagen as compared to the
corresponding control cells. A similar increase in cellular adhesive
property was also observed in the Hela Bit1 knockdown clones
relative to the control clone (Figure S1B). Since adhesion to matrix
proteins is also an important step in cell migration [14,15] we
examined the migratory potential of Bit1 knockdown cells.
Consistent with their enhanced adhesive properties, the stable
Hela knockdown clones showed an increase in migration relative
to control clones, as evidenced by in vitro wound closure (Figure 3E)
and modified Boyden chamber assays (Figure 3F).
It is possible the increased wound closure by the stable Hela Bit1
knockdown clones could be attributed to their increased
proliferative ability. To exclude this, we measured the proliferation
rates of the different clones in vitro. Interestingly, the stable Hela
knockdown clones exhibited a slower anchorage-dependent
growth rate relative to the control clones (Figure S1C). Such a
decrease in growth rate was also observed in MCF7-derived Bit1
knockdown pool as compared to the control pool (Figure S1D).
Hence, the observed increase in wound closure by the Hela Bit
knockdown clones is attributable to their enhanced migratory
ability as confirmed by the modified Boyden chamber migration
assay (Figure 3F). To verify that the enhanced migration of Hela
cells following Bit1 suppression is not cell line specific, the stable
Bit1 knockdown pools derived from MCF7 and B16F1 cells and
their corresponding control pool were subjected to modified
Boyden Chamber migration assay. Indeed, stable downregulation
of endogenous Bit1 in these cells resulted in enhanced migration
(Figure 3G for MCF7 and Figure 3H for B16F1 cells) as compared
to the control pool.
Activated Erk contributes to the increased adhesion and
migration of Bit1 knockdown cells
Mouse embryo fibroblasts lacking Bit1 and HeLa cancer cells
transiently and stably transfected with Bit1-specific siRNAs
exhibited enhanced levels of Erk activation [10]. In particular,
the suppression of Bit1 in these cells was associated with a marked
increase in the levels of the phosphorylated Erk2 isoform.
Consistent with these previous findings, downregulating endoge-
nous Bit1 in MCF7 (Figure 4A) and B16F1 cells (Figure 4B) also
resulted in increase of levels of phosphorylated (active) Erk2 with
no consistent changes in the levels of active MEK, an upstream
regulator of Erk.
To address the mechanism of Erk activation following Bit1
suppression, we examined the Erk-directed phosphatase activity in
Bit1 knockdown and control cells using a nonradioactive
phosphatase assay with phosphorylated Erk2 as the substrate.
Total cell lysate extract from Bit1 knockdown cells exhibited a
significant decrease in Erk dephosphorylation as compared with
that of control cells (Figure 4C and 4D).
The enhanced Erk activation has been shown to contribute to
the anoikis resistance of mouse embryo fibroblasts lacking Bit1 and
Bit1 knockdown cells, since siRNA-mediated downregulation of
endogenous Erk2 partially restored the anoikis sensitivity of these
cells [10]. Here, we examined the effects of inhibiting Erk
activation using the Erk2 specific siRNAs on the increased cellular
adhesion and migratory potential of Bit1 knockdown cells. The
Hela derived Bit1 knockdown cells were chosen for this study due
to its high transfectability. Downregulating Erk2 (Figure 4E)
significantly attenuated the increased cell adhesion (Figure 4F) and
migration (Figure 4G) of the Bit1 knockdown cells with no
significant effect on the low adhesion and migratory potential of
control cells. These findings indicate that Erk2 activation is likely
to contribute to the enhanced adhesion and migration of Bit1
knockdown cells.
Bit1 downregulation does not significantly influence
tumor growth but enhances metastasis
The stable MCF7 Bit1 and B16F1 Bit1 knockdown pool
produced subcutaneous tumors that grew at the same rate as
tumors obtained with the corresponding control cell pools (shown
for the B16F1 pool in Figure 5A). Interestingly, the lungs of the
mice with tumors from the B16F1 Bit1 knockdown pool showed
redness and swelling, suggesting the presence of lung metastases
(Figure 5B). Indeed, immunohistochemistry of the lungs derived
from these mice showed the presence of numerous microscopic
tumor foci while the mice that received the control pool exhibited
significantly fewer pulmonary colonies (Figure 5C and D).
To further examine the effect of Bit1 downregulation on
metastasis, we subjected the stable B16F1 and MCF7 Bit1
knockdown and the corresponding control pools to experimental
tail vein metastasis assays. The lungs of mice that received
injections of B16F1 Bit1 knockdown pool (Figure 5E and 5F) and
MCF7 Bit1 knockdown pool (Figure 5G and 5H) showed an
increase in the number of metastatic foci as compared to the lungs
derived from mice injected with control cells. We also observed
numerous tumor foci in the lungs of mice injected with HeLa Bit1
knockdown clones, while that of the control clone-treated mice
showed no visible signs of tumor infiltrates (Figure S1E). To
confirm the effect of Bit1 downregulation on metastatic pheno-
type, we also restored mitochondrial expression in the highly
aggressive and metastatic mouse melanoma B16F10 cell line
which shows low levels of endogenous Bit1. Expression of
exogenous mitochondrial Bit1 attenuated the high basal Erk
activation in B16F10 cells (Figure 5I) and significantly inhibited
the ability of these cells to form metastatic foci in lungs following
an experimental metastasis assay (Figure 5J). Taken together, these
findings implicate a role of Bit1 in metastasis.
Increased Erk phosphorylation in pulmonary metastases
To determine the role of Erk activation in the enhanced
metastasis of Bit1 knockdown cells, we stained the lung tissue from
mice injected with control and Bit1 knockdown cells using a
phospho-specific Erk1/2 antibody. The metastatic foci from Bit1
knockdown cells stained more strongly for phospho-Erk than foci
from control cells (Figure 6A). A much higher number of
metastatic foci from Bit1 knockdown cells were positive for
phospho-Erk 1/2 than foci from control cells (Figure 6B). In
primary tumors, the control and Bit1 knockdown cells exhibited
Bit1 Is a Regulator of Metastasis
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similar low levels of phosphorylated Erk staining (data not shown).
Thus, the upregulation of Erk phosphorylation in metastatic
tumors of Bit1 knockdown cells suggests that Erk activation may
be an important effector of metastasis following Bit1 suppression.
Discussion
Acquisition of anoikis resistance is a determinant of transfor-
mation and metastasis in tumor cells. In this paper, we examined
the possibility that Bit1 is downregulated in advanced stages of
cancer and that suppression or nonfunctionality of the Bit1 anoikis
pathway may contribute to tumor progression. Immunohisto-
chemistry of breast tumor tissue arrays revealed that Bit1 is
expressed in normal breast epithelial and Ductal Carcinoma In
Situ (DCIS) tissues while decrease or loss of Bit1 expression was
correlated with advanced invasive carcinoma tissues. In vitro studies
indicated that downregulating endogenous Bit1 expression
enhances the metastasis-associated properties in cultured tumor
cells. The Bit1 knockdown cells displayed decreased sensitivity to
anoikis, enhanced cell adhesion, increased migration, and high
levels of Erk activation. We also showed that suppression of Bit1
conferred enhanced metastatic potential to cancer cells in
experimental metastasis assays in vivo. These results indicate that
Bit1 is a negative regulator of metastasis, likely through reduced
Erk activation.
Our findings here illustrating Bit1 as a metastasis suppressor are
consistent with and reminiscent of a recent publication demon-
strating that AES, a pro-apoptotic binding partner of Bit1, is a
suppressor of colon carcinoma metastasis and has no effect on
tumorigenicity [13]. Interestingly, this paper also showed that
metastasis suppression by AES is through inhibition of tumor cell
migration, which is one of the pro-metastatic phenotypes observed
in Bit1 knockdown cells. Considering that AES is a critical
regulator of the Bit1 pathway, a possibility remains that AES acts
in conjunction with Bit1 (or vice versa) to suppress tumor
metastasis.
Tumor metastasis is a multistep process involving migration and
invasion of the extracellular matrix (ECM), adhesive interactions
with ECM components, intravasation through the vessel wall,
circulating in the blood vessels, and ultimately lodging into
secondary sites [16]. Importantly, while in transit through
lymphatic and blood circulation, metastatic cells must survive in
the absence of cell attachment-induced survival signals. Here, we
show that tumor cells with knocked down Bit1 exhibit several key
properties underlying the metastatic process. First, the Bit1
knockdown cells were resistant to anoikis, which may contribute
to the survival of these cells in the absence of cell attachment
during metastasis. Downregulating Bit1 also increased cell
attachment to the matrix proteins fibronectin and collagen.
Although tumor cell adhesion plays a complex role in metastasis
[17], the enhanced adhesive properties coupled to the enhanced
survival capacity may allow the Bit1 knockdown cells to adhere to
the target tissue during metastasis. The Bit1 apoptotic function is
uniquely controlled by an integrin mediated signalling pathway
[5]. The increased cellular adhesion following Bit1 suppression
suggests that Bit1 may regulate integrin activity through a
feedback mechanism. In agreement with this possibility, activation
of MAPK/Erk pathway, which Bit1 counteracts, activates integrin
[18,19].
Another important metastasis-associated property exhibited by
Bit1 knockdown cells is their increased motility. Although our data
indicate that the increase in motility is in part dependent on Erk
activation, this increase in motility may be a consequence of the
enhanced adhesive properties because tumor cell adhesion to
extracellular matrix components is important in cell migration
[17]. Active migration of tumor cells is a prerequisite of metastasis
and is one of the critical factors in epithelial- mesenchymal
transition (EMT), a process associated with metastatic progression
[20]. The morphological changes observed in Bit1 knockdown
HeLa cells are consistent with the EMT phenotype, but it remains
to be investigated whether Bit1 affects the EMT process. Our
recent findings of the loss of E-cadherin and upregulation of N-
cadherin expression (Figure S1F) in Hela Bit1 knockdown cells
support this possibility.
Interestingly, the Bit1 knockdown cells showed decreased cell
growth in adherent culture conditions as compared to control cells
(Figure S1C–S1D [21]). The reduction of growth was observed in
several cancer cell lines following suppression of endogenous Bit1
protein, suggesting that this effect is specific to Bit1 downregula-
tion. Based on crystal structural studies [22], Bit1 contains a
peptidyl tRNA hydrolase domain which is distinct from its
apoptotic domain. It is conceivable that the native mitochondrial
Bit1 may impact cellular translation process and subsequent cell
growth via its tRNA hydrolase enzymatic function. Consistent
with this notion, ectopic overpression of the tRNA hydrolase
domain of Bit1 in cultured cells resulted in enhanced cell growth
(unpublished data). This dual functionality of Bit1 is reminiscent of
another mitochondrial protein namely Apoptosis Inducing Factor
(AIF) in controlling cellular life and death. AIF exhibits pro-
apoptotic caspase-independent activity following its release from
the mitochondria and functions as a survival factor via its
oxidoreductase activity when localized in native mitochondria
[23].
The metastasis-associated properties of the Bit1 knockdown cells
appear to involve the Erk survival pathway. Bit1 is a negative
regulator of Erk activity; mouse embryonic fibroblasts from Bit1
knockout mice, as well as cultured HeLa cells treated with Bit1-
specific siRNAs, exhibit enhanced levels of active (phosphorylated)
Erk [10]. This Erk activation contributes in part to the enhanced
anoikis resistance of the cells. In this report, downregulation of
Bit1 in MCF7 and B16F1 cells also increased the levels of
phosphorylated Erk2, the isoform which is specifically affected by
Bit1 [10]. Furthermore, suppressing Erk activity via Erk2 specific
siRNAs attenuated the enhanced adhesion and migratory capacity
Figure 3. Downregulation of Bit1 results in morphological changes and enhances cellular adhesion and migration. A and B. The
morphology of controlshRNA and Bit1shRNA knockdown pools derived from MCF7 (A) and B16F1 (B) was examined by phase contrast microscopy
(1006magnification) under normal culture conditions. C and D. Stable control shRNAcontrol and Bit1shRNA knockdown pools derived from MCF7 (C)
and B16F1(D) were seeded in 96-well plates precoated with fibronectin, collagen I, or BSA. After 15 min of incubation at 37uC, the number of
adherent cells was determined by staining with green fluorescent dye (calcein-AM) followed by fluorescence measurement as described under
Materials and Methods (Innocyte Cell Adhesion Assay Kit, EMD Biosciences). E. Stable control and Bit1 Hela knockdown clones were subjected to a
wound repair assay. The wound was generated at time 0 h and cell migration into the wound was analyzed by phase contrast microscopy at 16 h. F,
G, and H. Control and Bit1 knockdown cells derived from Hela (F), MCF7 (G), and B16F1 (H) were subjected to a QCM 96-well migration boyden
chamber assay wherein the number of cells that migrated to the bottom of the insert membrane was quantified by CyQuant Gr dye (Molecular
Probes) as described in Materials and Methods. In C, D, F, G, and H, results are representative of three independent experiments, *p,0.05 as
compared with the control cells (Student’s t test).
doi:10.1371/journal.pone.0023840.g003
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Figure 4. Bit1 negatively regulates Erk activation through decreased Erk phosphatase activity, and Erk down-regulation attenuates
the enhanced cell adhesion and motility of Bit1 knockdown cells. A and B. Exponentially growing stable controlshRNA and Bit1shRNA
knockdown pools derived from MCF7(A) and B16F1(B) were lysed, and the total lysate was subjected to immunoblotting to detect the
phosphorylated Erk (pErk), total Erk(tErk), active Mek (pMek), total Mek (tMek), Bit1, and b-actin. C and D. Total cell lysates from stable
MCF7controlshRNA and Bit1shRNA knockdown pools were subjected to an Erk phosphatase assay as described in Materials and Methods. A
representative immunoblot of isolated His-6-tagged Erk2 is shown to reveal pErk2 or total Erk2 levels (C). The relative intensity of pErk2/tErk was
determined using NIH Image J software, and the values represent the average of at least three independent experiments (D). E, F and G. Stable Hela
control clone#1 and Bit1RNAi#21 clone were transfected with control- or Erk2-specific siRNAs; 48 h post-transfection, cells were harvested and
Bit1 Is a Regulator of Metastasis
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of Bit1 knockdown cells, indicating the involvement of the Erk
pathway in Bit1 regulation of cell adhesion and motility. Based on
the recent report demonstrating that the anti-invasive and anti-
metastasis function of AES is through inhibition of the Notch
signalling [13], it remains to be determined whether Bit1 also
regulates this pathway.
The mechanism of Erk regulation by Bit1 remains to be fully
elucidated, but available evidence suggests that Bit1 inhibits Erk
activation through induction of Erk-specific phosphatases. The
Bit1 knockout and knockdown cells with elevated Erk activation
show no changes in activation of the upstream regulators of Erk,
the AKT and MEK kinases, but Erk-directed phosphatase activity
is significantly decreased in these cells (Figure 4C-4D [10]).
Interestingly, cell adhesion, which regulates the apoptotic activity
of Bit1, also regulates Erk phosphatase function [24,25]. In
particular, cell adhesion decreases, and detachment increases Erk-
directed phosphatase activity. To date, several phosphatases for
Erk have been identified, including CDC25A, He-PTP, and
several MAP kinase phosphatases (MKPs) [24,25]. It is noteworthy
that the activity of MKP3/DUSP6 has been shown to be regulated
by cell adhesion and suppresses the anchorage-independent
activation of Erk2 induced by vinexin b, a focal adhesion scaffold
protein [25], making this phosphatase a likely Bit1 target.
Interestingly, the Scansite 2.0 Motif program [26] identifies an
Erk binding site in Bit1. Whether Bit1 associates with Erk and how
such an interaction impinges on Erk activity remain to be
investigated.
Consistent with the in vitro findings, the Bit1 knockdown cells
exhibited enhanced capacity to produce metastatic tumors as
compared to control cells. In particular, we observed increased
metastasis both from subcutaneous tumors and from intravenously
injected Bit knockdown tumor cells. In keeping with the in vitro
results suggesting Erk involvement in the Bit1 effects, the
metastatic tumors derived from Bit1 knockdown cells exhibited
significantly positive staining for phosphorylated Erk. A number of
reports documents the importance and requirement of the Erk
pathway in promoting cancer cell motility, invasion, and
metastasis in various tumors [7,8,9]. In particular, analyses of
the Erk activation in the experimental metastasis model of MEK
transformed cells demonstrated a requirement for Erk activity in
the acquisition of advanced stages of cancer progression,
particularly in promoting tumor cell invasion and metastasis
[9,27]. Given that Erk activity underlies in part the observed
enhanced anoikis resistance, cellular adhesion and motility in Bit1
knockdown cells in vitro, together with the enhanced Erk
phosphorylation in pulmonary tumors in vivo, reduction of Bit1
expression may enhance the metastatic ability of cells at least in
part by potentiating Erk signalling.
Interestingly, we found no significant differences in the basal
Erk activation in primary tumors derived from control and Bit1
knockdown cells. This finding is consistent with the possibility that
the effect of Bit1 on Erk activity is dispensable during primary
tumor growth. The complex rich microenvironment and the
presence of multiple redundant oncogenic survival pathways at the
primary tumor site in vivo may reduce the requirement for and
hence, mask the effect of Bit1 on Erk-mediated signaling during
tumor growth. In line with this notion, non-invasive, benign like
clonal expansion or growth of MEK transformed cells did not
require Erk activation and was associated with diminished levels of
Erk [9,27]. Given the critical role of the Erk activity in invasion
and metastatic processes [9,27], we propose that the effect of Bit1
knockdown on Erk signalling becomes potentiated or more evident
when cells loose contact with the primary site during invasion and
metastasis. Endowed with enhanced Erk activation potential, the
Bit1 knockdown cells may then be selected for increased metastatic
potential. In support of this hypothesis, we found that downreg-
ulation of Bit1 specifically enhanced the metastatic property of
tumor cells with no significant impact on their tumorigenicity, and
the metastatic foci of Bit1 knockdown cells showed increased Erk
activation.
In summary, we have uncovered that downregulation of Bit1
expression conferred tumor cells with pro-metastatic phenotypes in
vitro and specifically potentiated metastasis in vivo. Thus, the
suppression of Bit1 in human tumor specimens, as evidenced in
advanced stages of human breast cancer (Figure 1A–1C) may
contribute to a more aggressive and metastatic disease.
Materials and Methods
Cell culture and transfection assays
MCF7, B16F1 and B16F10 cell lines from American Type
Culture Collection (ATCC) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) with glutamine containing 10% fetal
bovine serum, penicillin, and streptomycin, while the stable Hela
control and Bit1 knockdown clones were cultured in DMEM
glutamine containing 10% fetal bovine serum, penicillin, and
streptomycin with 250 ug/ml G418 [10]. Transfections were
carried out with lipofectamine 2000 (Invitrogen) in OPTI-MEM
(Invitrogen) according to the manufacturer’s protocol with cells
plated 18 hr before transfection. The total amount of plasmid used
per transfection was normalized with the corresponding empty
vector constructs.
Chemical reagents, antibodies, and plasmids
Poly(2-hydroxyethyl methacrylate (Polyhema) and the mouse
monoclonal anti-b-actin antibody were obtained from Sigma
Chemical Co. (St. Louis, Mo.). The E-cadherin, N-cadherin, anti-
total Erk, anti-phosphoErk, anti-Erk2, anti-MEK, and anti-
phospho MEK polyclonal antibodies were obtained from Cell
Signaling Technology (Beverly, MA). FITC-conjugated secondary
anti-rabbit antibody was purchased from Molecular Probes
(Eugene, OR). The anti-Bit1 antibody and the mammalian
expression vector encoding for mitochondrial Bit1 were generated
as described previously [5]. The specific antibody to Bit1 used for
immunoblotting was generated as described previously [5], and
the affinity purified rabbit anti-Bit1 antibody (HPA012897, Sigma)
was used for immunohistochemisry studies.
Lentiviral shRNA infection
MCF7 and B16F1 cells were infected with control- or Bit1-
shRNA lentiviral particles (Santa Cruz Biotechnology) in a six-
well plate format in the presence of polybrene (5 ug/ml). 24 h
post-infection, cells were treated with puromycin (2 ug/ml and
4 ug/ml for MCF7 and B16F1, respectively) to select for stable
control and Bit1 knockdown clones. Several puromycin resistant
control and Bit1 knockdown clones were harvested by ring-
cloning, and the level of Bit1 knockdown was confirmed by
immunoblotting against a specific Bit1 antibody. Two con-
subjected to immunoblotting (E) with antibodies against total Erk2 and phosphorylated Erk1/2 (pErks). In parallel, cells were subjected to a
fibronectin cell adhesion (F) and QCM boyden chamber migration assays (G) as described in Materials and Methods. In D, F and G, results are
representative of three independent experiments, *p,0.05 (Student’s t test).
doi:10.1371/journal.pone.0023840.g004
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trolshRNA clones and three positive Bit1shRNA knockdown
clones were pooled together to generate the controlshRNA pool
and Bit1shRNA pool, respectively. The resulting controlshRNA
and Bit1shRNA pools were subjected to immunoblotting using a
specific antibody to Bit1 to confirm the downregulation of Bit1
expression.
SiRNA transfection
The control and ERK2 specific siRNAs were purchased from
Santa Cruz Biotechnology. To downregulate Erk2 in a stable Bit1
Hela knockdown clone, 26105 cells were transfected with 25 mM
of ERK2 siRNAs with the use of Lipofectamine 2000 reagent.
48 hrs post-transfection, cells were harvested and analyzed by i)
Figure 5. Suppression of Bit1 enhances tumor metastasis with no significant effect on tumor growth in vivo. A, B, C, and D. Stable
B16F1 controlshRNA and Bit1shRNA knockdown pools were injected subcutaneously in BALB/c nude mice. A total of 20 mice were analyzed with 10
mice injected with control shRNA pool cells while another 10 mice injected with Bit1shRNA pool cells. At the indicated times after injection, tumor
volumes were measured (A). At the end of study, the lungs from mice were harvested and photographed (the representative lungs are shown in (B)
and random serial sections of paraffin-embedded lung tissue were examined by H&E staining to detect the presence of tumor foci (C) and the
numbers of pulmonary metastatic foci were counted (D), *P,0.05 as compared to control shRNA pool. E, F, G and H. Stable control and Bit1
knockdown pools from B16F1 (E and F) and MCF7 (G and H) were injected into the tail vein in BALB/c nude mice. For B16F1, a total of 20 mice were
analyzed with 10 tail vein injected with controlshRNA pool and another 10 mice injected with Bit1shRNA. A similar number of mice was used for
control shRNA and Bit1shRNA pools derived from MCF7. The mice were sacrificed 30 days post-injection for MCF7cells (20 days for B16F1), and the
lungs were harvested and metastatic colonies quantified in serial sections of H&E-stained, paraffin-embedded lung tissue (F and H), *P,0.05 as
compared with controlshRNA pool. In E, the representative lungs from mice injected with B16F1 Bit1 knockdown pool showed an obvious increase in
metastatic foci on the lung surface relative to that of controlshRNA pool. In G, representative serial sections of H&E-stained, paraffin-embedded lung
tissue from mice injected with stable MCF7 controlshRNA or Bit1shRNA knockdown pool are shown. I and J. B16F10 cells were transfected with vector
control or C-terminally myc tagged, mitochondrial localized myc-tagged Bit1 construct (Bit1 mito), and 24 h post-transfection, adherent cells were
harvested and subjected to immunoblotting against the antibody to myc, pErk, tErk, and b-actin (I). In parallel, vector and mitochondrial Bit1
transfected cells were injected into the tail vein (J) with 10 mice injected with vector control cells and another 10 mice injected with mitochondrial
Bit1 transfected cells. 20 days following injection, lungs were harvested and metastatic foci in lung tissue was quantified as described above, *P,0.05
as compared with vector control cells.
doi:10.1371/journal.pone.0023840.g005
Figure 6. Erk phosphorylation is up-regulated in pulmonary metastatic foci of Bit1 knockdown cells. A. Random serial sections of
paraffin-embedded lung tissue derived from mice injected tail vein with stable B16F1controlshRNA or Bit1shRNA knockdown pools were subjected to
immunofluorescence analysis of active Erk using anti-phosphorylated Erk antibody (1:100) as the primary antibody followed by incubation with FITC-
conjugated secondary antibody as described in Materials and Methods. Representative staining are shown in (A). B. The number of metastatic tumor
foci staining positive for pErk was quantified by examining serial sections of paraffin-embedded lung tissue of mice tail vein injected with stable
B16F1controlshRNA or Bit1shRNA knockdown pools. A total of sixty metastatic lesions (30 controlshRNA and 30 Bit1shRNA) from 10 animals (5 tail
vein injected with control shRNA pool and 5 tail injected with Bit1shRNA pool) were analyzed, *p,0.01 (Student’s t test).
doi:10.1371/journal.pone.0023840.g006
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immunoblotting with antibodies against Erk2 (Cell Signaling) to
confirm the downregulation of ERK2 or ii) migration assay as
described below.
Analysis of anoikis
To assess for anoikis cell death, cells were plated in Poly-HEMA
coated 96 well plates in complete growth medium containing 0.5%
methylcellulose at a density of 1.06104/well for 48 h. Suspension
cultures were prepared by plating cells on dishes coated with poly-
HEMA (Sigma) and culturing in serum-containing medium Cells
were collected and subjected to an apoptosis assay [6]. Apoptosis
was assessed by determining the level of cytosolic nucleosomal
fragments with the use of Cell Death Detection ELISA Kit
according to the manufacturer’s instructions (Roche Molecular
Biochemicals) and by Annexin V staining (Biovision) which was
analyzed by flow cytometry (BD FACS StarPlus) as prescribed by
the manufacturer.
Cell proliferation, cell adhesion and migration assays
To determine cell proliferation, cells were plates in a volume of
150 ml at a density of 2,000 cells per well in 96-well plates. At each
indicated time, the number of metabolically active cells was
measured with the use of MTT (Thiazolyl Blue Tetrazolium
Bromide, Sigma). Briefly, fifteen ml of MTT solution (5 mg/ml in
PBS) was added and further incubated for 4 h. The resulting
MTT formazan was solubilized by addition of 100 ml of SDS
solution (20% in 10 mM HCL), and the absorbance was measured
24 h at 550 nm and a reference wavelength of 690 nm using a
microplate reader. In cell adhesion experiments, 26104 cells were
seeded in 96-well plates precoated with fibronectin, collagen type
1, or BSA (Innocyte ECM Cell Adhesion Assay Kit, EMD
Biosciences) for 15 min at 37C, and cells were subsequently twice
washed with PBS to remove non-adherent cells. Following
extensive washing, attached cells were quantified by staining with
the green fluorescent dye calcein-AM according to manufacturer’s
protocol. The migration potential cells were determined by a
wound closure and a QCM Chemotaxis 96-well cell migration
assays. In wound closure experiments, cell monolayers were
scarred with a sterile micropipette tip and incubated for another
16 h. For each sample, three defined areas were monitored during
the time period and photographs were taken at time 0 h and 16 h
(magnification, X100). Using the QCM 96-well migration assay kit
(Chemicon), 2.56104 cells were added into the top chamber of a
boyden chamber in 100 ul of serum free DMEM medium. After
24 h of incubation, migratory cells on the bottom of the insert
were dissociated from the membrane using the Cell Detachment
Buffer according to manufacturer’s protocol. The cells are then
lysed and detected by fluorescent CyQuant GR dye (Molecular
Probes).
Protein preparation and western blotting assays
Protein preparation and western blotting were performed as
described previously [6]. Briefly, cells were harvested 24–48 hr
after transfection with various constructs or siRNAs by adding ice-
cold NP-40 lysis buffer (1% NP-40; 20 mM Tris-HCL [pH 7.4];
150 mM NaCl; 10% glycerol, 2 mM sodium vanadate; 1 mM
henylmethylsulfonyl fluoride; 10 mg/ml leupeptine; and 5 mg/ml
aprotinin) and incubating at 4uC for 20 min. For immunoblot
analysis, equal amounts of proteins were resolved on 4–20%
gradient Tris-glycine gels (Invitrogen) and electrophoretically
transferred to nitrocellulose membrane. The membranes were
incubated with primary antibodies overnight at 4uC followed by
secondary antibodies conjugated with horseradish peroxidase.
Membranes were developed using the ECL detection system.
Erk Phosphatase Assay
The in vitro Erk phosphatase assay is based on detecting
dephosphorylation of a purified, phosphorylated, His6-tagged Erk2
upon incubation with total cell lysate [10]. Briefly, 100 mg of cell
lysate prepared without phosphatase inhibitors was diluted 1:4 in
phosphatase assay buffer [10 mMMgCl2, 10 mM Hepes (pH 7.4),
and 10 mM Mek inhibitor UO126] and incubated with 30 ng of
recombinant phosphorylated His6-tagged Erk2 (Biomol) at room
temperature for 30 min. The reaction was terminated by adding
8 M urea (pH 8.6) containing 10 mM imidazole, and the samples
were placed on ice. The His-Erk2 was subsequently captured by
adding nickel-conjugated agarose and incubating at 4uC for
90 min. The samples were washed three times with 8 M urea
(pH 8.6) and 10 mM imidazole and two times in 300 mM NaCl2
and 25 mM Tris (pH 7.5). The amount of remaining phosphor-
ylated His-Erk2 was determined by immunoblotting using a
specific antibody to phosphorylated ERK. The amount of total
ERK was also determined using a antibody against total ERK to
account for protein loading.
In vivo tumorigenesis and metastasis assays
All procedures were done according to protocols approved by
the Institutional Committee for Use and Care of Laboratory
Animals of University of California, Santa Barbara (UCSB
Approved Protocol 5-010-733 R). Eight-week-old female athymic
nude mice (BALB/c) were used for the tumorigenesis assays. The
indicated MCF7, or B16F1 cells (16106) were injected subcuta-
neously into the flank. The tumor sizes were measured periodically
with a calliper, and tumor volume was determined with the
formula (d16d22)/2 where d1 represents the larger diameter and
d2 the smaller diameter. Mice were sacrificed when the primary
tumors reached 2 cm in diameter and tumors and lungs were
excised and subjected to immunohistochemistry for analysis of
metastasis. In experimental metastasis assay, 16106 cells (for
MCF7 and HeLa) or 0.56106 cells (for B16F series) in 100 ml PBS
were injected into the lateral vein of athymic BALB/c nude mice.
Thirty days (for MCF7 and Hela cells) and twenty days (for B16F
series cells) after the injection, the mice were euthanized. The
lungs were dissected out, photographed, fixed in 4% PFA
overnight, cryoprotected in 30% sucrose in PBS and frozen in
OCT embedding media (Tissue Tek). Serial sections of the lungs
were stained with H&E, and the number of pulmonary colonies
was counted under a light microscope.
Immunofluorescence microscopy
For immunostaining, 5 mm lung tumor tissue section slides were
deparafinized in xylene for 10 minutes, hydraded through graded
alcohols, rinsed with 1xPBS, blocked in 5% serum/2% albumin in
PBS for 1 h at room temperature, and then followed by incubation
with the primary antibody diluted in blocking buffer for overnight
at 4uC. The primary antibodies were subsequently detected by
incubation with secondary antibodies coupled to FITC for 1 h at
room temperature. Nuclei were visualized by counterstaining with
496-diamidino-2-phenylindole (DAPI). Samples were then ana-
lyzed using a Carl Zeiss fluorescence microscope.
Human breast tumor array analysis
Breast tumor tissue array slides containing intraductal carcino-
mas, invasive ductal carcinoma (lymph node negative), and
metastatic invasive ductal carcinoma to the lymph node (lymph
node positive) with matched normal breast epithelial tissue were
obtained from US Biomax, Inc. (Rockville, MD). Based on two
tissue microarray slides, a total of 55 intraductal carcinomas, 45
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lymph node negative invasive ductal carcinomas, and 40 lymph
node positive invasive ductal carcinomas were included for
analysis. The immunohistochemistry procedure was performed
by Biomax Inc. Briefly, tissue array slides were deparaffinised,
hydrated and subjected to antigen retrieval. The slides were then
incubated in 2.5% normal horse serum for 30 min at room
temperature followed by incubation with the purified rabbit anti-
Bit1 antibody (1:100 dilution) for 1 h at room temperature. Rabbit
normal serum was used as negative control antibody to replace the
primary antibody on control slide with 1 hr incubation. Tissue
array slides were then washed and incubated with ImmPRESS
reagent (Vector Laboratories) followed by treatment with
peroxidise substrate DAB solution (DAKO Cytomation). Each of
the experimental and control slide was scored for average staining
intensity by two investigators with no knowledge of the pathologic
status of the samples. These investigators scored staining intensity
as 0, no staining; 1 low staining; 2 medium staining; or 3 high
staining.
Statistical Analysis
Data are presented as means (6S.E.). For western blots and
anoikis assays, experiments were performed at least three times
with duplicates. Statistical differences between groups were
established at a P value,0.05 using the two-tailed Student’s t
test. For breast tumor tissue array analysis, a one-way ANOVA
with subsequent post hoc testing using the Tukey-Kramer multiple
comparison test was used to compare the average staining intensity
of each case type. ANOVA analysis indicated a significant
difference (P,0.01) between the normal/DCIS and the node
negative and node positive invasive subgroups. Additional post-
hoc analysis indicated no significant difference between normal
and DCIS subgroups (P.0.1), but significant differences between
normal/DCIS and invasive node negative (P,0.01) and invasive
node positive (P,0.01) subgroups. Further post-hoc testing
showed significant difference (P,0.05) between the invasive node
negative and invasive node positive subgroups. All calculations
were done using the NCSS statistical software (NCSS, Kasville,
UT).
Supporting Information
Figure S1 Effects of stable suppression of Bit1 in Hela
and MCF7 cells. A. The morphology of exponentially growing
stable Bit1 knockdown and control clones previously established in
the Hela cancer cell line [10] was examined by phase contrast
microscopy (1006magnification). B. The Hela control and Bit1
knockdown clones were seeded in 96-well plates precoated with
fibronectin, collagen I, or BSA. After 15 min of incubation at
37uC, the number of adherent cells was determined by staining
with green fluorescent dye, calcein-AM followed by fluorescense
measurement as described under Materials and Methods. C and
D. Stable Bit1 knockdown and control cells derived from Hela (C)
and MCF7(D) parental lines were subjected to MTT assay (see
Materials and Methods) to quantify their anchorage-dependent
growth. E. The stable HeLa Bit1 knockdown and control clones
were injected into the tail vein using 10 mice per clone, and 30
days after injection the lungs were harvested and metastatic
colonies were quantified in random serial sections of H&E-stained,
paraffin-embedded lung tissue. F. Exponentially growing stable
HeLa Bit1 knockdown and control clones were lysed, and the
resulting total lysate was subjected to immunoblotting using the
antibodies against E-cadherin, N-cadherin, and b-actin. In B, C, D
and E, results are representative of three independent experiments,
*p,0.05 (compared to control cells, Student’s t test).
(TIF)
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